Maintenance therapy for cytogenetically high-risk multiple myeloma: landscape in the era of novel drugs

被引：2

作者：

Gu, Xinyuan ^{[1
,2
]}

Tang, Wenjiao ^{[1
]}

Zhang, Li ^{[1
]}

Zheng, Yuhuan ^{[1
]}

Pan, Ling ^{[1
]}

Niu, Ting ^{[1
]}

机构：

[1] Sichuan Univ, West China Hosp, Inst Hematol, Dept Hematol, 37 Guo Xue Xiang St, Chengdu 610041, Peoples R China

[2] Sichuan Univ, Chengdu, Peoples R China

来源：

CLINICAL AND EXPERIMENTAL MEDICINE | 2024年 / 24卷 / 01期

关键词：

High risk; Maintenance; Myeloma; Network meta-analysis; Real-world study; STEM-CELL TRANSPLANTATION; OPEN-LABEL; SURVIVAL OUTCOMES; DEXAMETHASONE RVD; ORAL IXAZOMIB; PATIENTS PTS; LENALIDOMIDE; BORTEZOMIB; THALIDOMIDE; TRIAL;

D O I：

10.1007/s10238-024-01445-6

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Although the significant strides in novel therapeutic approaches have prolonged the survival of multiple myeloma (MM) patients, the unfavorable prognosis of cytogenetically high-risk newly diagnosed MM (NDMM) remains intractable with the lack of consensus regarding the choice of maintenance regimens. Therefore, this study was initiated with the aim of examining the effectiveness of various maintenance treatments for this group of patients in jeopardy. Overall, 17 studies with 1937 high-risk NDMM patients were included in the network meta-analysis. Combination therapies involving novel drugs presented encouraging prospects in the maintenance phase, while the patients and circumstances for the application of different regimens still needed to be further distinguished and clarified. To investigate the current status of maintenance therapy of high-risk NDMM patients in clinical practice, a real-world cohort of high-risk NDMM was retrospectively incorporated 80 patients with lenalidomide maintenance and 53 patients with bortezomib maintenance, presenting the median PFS of 31.7 months and 30.4 months, respectively (p = 0.874, HR = 0.966, 95% CI: 0.628-1.486). Collectively, this study illuminated the present constraints of conventional approaches during the maintenance phase for high-risk NDMM patients while highlighting the future potential associated with enhanced regimens integrating novel medications.

引用

页数：12

共 57 条

[11] Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma [J].

Costa, Luciano J. ;

Chhabra, Saurabh ;

Medvedova, Eva ;

Dholaria, Bhagirathbhai R. ;

Schmidt, Timothy M. ;

Godby, Kelly N. ;

Silbermann, Rebecca ;

Dhaka, Binod ;

Bal, Susan ;

Gid, Smith ;

D'Souza, Anita ;

Hall, Aric ;

Hardwick, Pamela ;

Omel, James ;

Cornell, Robert F. ;

Had, Parameswaran ;

Callander, Natalie S. .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (25) :2901-+

[12] Diagnosis and Management of Multiple Myeloma A Review [J].

Cowan, Andrew J. ;

Green, Damian J. ;

Kwok, Mary ;

Lee, Sarah ;

Coffey, David G. ;

Holmberg, Leona A. ;

Tuazon, Sherilyn ;

Gopal, Ajay K. ;

Libby, Edward N. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (05) :464-477

[13] Checking consistency in mixed treatment comparison meta-analysis [J].

Dias, S. ;

Welton, N. J. ;

Caldwell, D. M. ;

Ades, A. E. .

STATISTICS IN MEDICINE, 2010, 29 (7-8) :932-944

[14] Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial [J].

Dimopoulos, Meletios A. ;

Spicka, Ivan ;

Quach, Hang ;

Oriol, Albert ;

Hajek, Roman ;

Garg, Mamta ;

Beksac, Meral ;

Bringhen, Sara ;

Katodritou, Eirini ;

Chng, Wee-Joo ;

Leleu, Xavier ;

Iida, Shinsuke ;

Mateos, Maria-Victoria ;

Morgan, Gareth ;

Vorog, Alexander ;

Labotka, Richard ;

Wang, Bingxia ;

Palumbo, Antonio ;

Lonial, Sagar .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (34) :4030-4041

[15] Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial [J].

Dimopoulos, Meletios A. ;

Gay, Francesca ;

Schjesvold, Fredrik ;

Beksac, Meral ;

Hajek, Roman ;

Weisel, Katja Christina ;

Goldschmidt, Hartmut ;

Maisnar, Vladimir ;

Moreau, Philippe ;

Min, Chang Ki ;

Pluta, Agnieszka ;

Chng, Wee-Joo ;

Kaiser, Martin ;

Zweegman, Sonja ;

Mateos, Maria-Victoria ;

Spencer, Andrew ;

Iida, Shinsuke ;

Morgan, Gareth ;

Suryanarayan, Kaveri ;

Teng, Zhaoyang ;

Skacel, Tomas ;

Palumbo, Antonio ;

Dash, Ajeeta B. ;

Gupta, Neeraj ;

Labotka, Richard ;

Rajkumar, S. Vincent ;

Bar, Daniel ;

Basso, Alfredo ;

Fantl, Dorotea ;

He, Simon ;

Horvath, Neomi ;

Lee, Cindy ;

Rowlings, Phillip ;

Taylor, Kerry ;

Cochrane, Tara ;

Kwok, Fiona ;

Ramanathan, Sundreswran ;

Agis, Hermine ;

Zojer, Niklas ;

Kentos, Alain ;

Offner, Fritz ;

Van Droogenbroeck, Jan ;

Wu, Ka Lung ;

Maiolino, Angelo ;

Martinez, Gracia ;

Zanella, Karla ;

Capra, Marcelo ;

Araujo, Sergio ;

Gregora, Evzen ;

Pour, Ludek .

LANCET, 2019, 393 (10168) :253-264

[16] Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial [J].

Durie, Brian G. M. ;

Hoering, Antje ;

Abidi, Muneer H. ;

Rajkumar, S. Vincent ;

Epstein, Joshua ;

Kahanic, Stephen P. ;

Thakuri, Mohan ;

Reu, Frederic ;

Reynolds, Christopher M. ;

Sexton, Rachael ;

Orlowski, Robert Z. ;

Barlogie, Bart ;

Dispenzieri, Angela .

LANCET, 2017, 389 (10068) :519-527

[17] Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial [J].

Dytfeld, Dominik ;

Wrobel, Tomasz ;

Jamroziak, Krzysztof ;

Kubicki, Tadeusz ;

Robak, Pawel ;

Walter-Croneck, Adam ;

Czyz, Jaroslaw ;

Tyczynska, Agata ;

Druzd-Sitek, Agnieszka ;

Giannopoulos, Krzysztof ;

Nowicki, Adam ;

Szczepaniak, Tomasz ;

Lojko-Dankowska, Anna ;

Matuszak, Magdalena ;

Gil, Lidia ;

Pula, Bartosz ;

Rybka, Justyna ;

Majcherek, Maciej ;

Usnarska-Zubkiewicz, Lidia ;

Szukalski, Lukasz ;

Konska, Agnieszka ;

Zaucha, Jan Maciej ;

Walewski, Jan ;

Mikulski, Damian ;

Czabak, Olga ;

Robak, Tadeusz ;

Lahoud, Oscar B. ;

Zonder, Jeffrey A. ;

Griffith, Kent ;

Stefka, Andrew ;

Major, Ajay ;

Derman, Benjamin A. ;

Jakubowiak, Andrzej J. .

LANCET ONCOLOGY, 2023, 24 (02) :139-150

[18] Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis [J].

Facon, Thierry ;

San-Miguel, Jesus ;

Dimopoulos, Meletios A. ;

Mateos, Maria-Victoria ;

Cavo, Michele ;

van Beekhuizen, Sophie ;

Yuan, Zijiao ;

Mendes, Joao ;

Lam, Annette ;

He, Jianming ;

Ammann, Eric ;

Kumar, Shaji .

ADVANCES IN THERAPY, 2022, 39 (05) :1976-1992

[19] Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial [J].

Facon, Thierry ;

Kumar, Shaji K. ;

Plesner, Torben ;

Orlowski, Robert Z. ;

Moreau, Philippe ;

Bahlis, Nizar ;

Basu, Supratik ;

Nahi, Hareth ;

Hulin, Cyrille ;

Quach, Hang ;

Goldschmidt, Hartmut ;

O'Dwyer, Michael ;

Perrot, Aurore ;

Venner, Christopher P. ;

Weisel, Katja ;

Mace, Joseph R. ;

Raje, Noopur ;

Tiab, Mourad ;

Macro, Margaret ;

Frenzel, Laurent ;

Leleu, Xavier ;

Ahmadi, Tahamtan ;

Wang, Jianping ;

Van Rampelbergh, Rian ;

Uhlar, Clarissa M. ;

Tromp, Brenda ;

Delioukina, Maria ;

Vermeulen, Jessica ;

Usmani, Saad Z. .

LANCET ONCOLOGY, 2021, 22 (11) :1582-1596

[20] Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma [J].

Facon, Thierry ;

Venner, Christopher P. ;

Bahlis, Nizar J. ;

Offner, Fritz ;

White, Darrell J. ;

Karlin, Lionel ;

Benboubker, Lotfi ;

Rigaudeau, Sophie ;

Rodon, Philippe ;

Voog, Eric ;

Yoon, Sung-Soo ;

Suzuki, Kenshi ;

Shibayama, Hirohiko ;

Zhang, Xiaoquan ;

Twumasi-Ankrah, Philip ;

Yung, Godwin ;

Rifkin, Robert M. ;

Moreau, Philippe ;

Lonial, Sagar ;

Kumar, Shaji K. ;

Richardson, Paul G. ;

Rajkumar, S. Vincent .

BLOOD, 2021, 137 (26) :3616-3628

← 1 2 3 4 5 6 →